Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Vibe Growth Corporation (VIBEF)
Sacramento, CA, US
Vibe Growth Corporation operates across various segments of the cannabis industry, catering to both recreational and medical consumers. The company is involved in the full spectrum of activities, including cultivating, producing, manufacturing, and distributing cannabis products. Its operational footprint includes five retail dispensaries, two cultivation facilities, and a dedicated distribution center. Products are also accessible to customers through its online platform, operating under the 'Vibe By California' brand, which offers e-commerce and home delivery services. Specializing in indoor cultivation, Vibe Growth Corporation handles commercial distribution, transportation, and manufacturing of its marijuana products. Established in 2020, the company was initially known as Vibe Bioscience Ltd. before officially rebranding to Vibe Growth Corporation in October of the same year. It maintains its headquarters in Sacramento, California.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -14.52% | -5.42% | -14.52% | -14.84% | -51.16% | -92.80% | -99.52% | -99.29% | -99.29% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+37.9% ★ Q1'26: +24.4% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+62.3% ★ Q1'26: -141.9% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+0.8% Q1'26: +5.2% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+2.6% Q1'26: -0.5% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%— Q1'26: +1.4% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.72× Q1'26: 2.70× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2026 1 Rev. Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
24.24M
est: 23.90M (+1.4%)
|
29.29M
est: 30.75M (-4.8%)
|
20.71M
est: 25.67M (-19.3%)
|
14.15M
est: 29.58M (-52.2%)
|
23.90M
23.90M – 23.90M
-19.2% YoY
|
30.75M
30.75M – 30.75M
+28.7% YoY
|
25.67M
25.67M – 25.67M
-16.5% YoY
|
29.58M
29.58M – 29.58M
+15.2% YoY
|
| EBITDA |
2.58M
est: -4.99M (+151.7%)
|
-1.10M
est: -6.42M (+82.9%)
|
-3.63M
est: -5.36M (+32.3%)
|
-8.57M
est: -6.18M (-38.8%)
|
-4.99M
-4.99M – -4.99M
+19.2% YoY
|
-6.42M
-6.42M – -6.42M
-28.7% YoY
|
-5.36M
-5.36M – -5.36M
+16.5% YoY
|
-6.18M
-6.18M – -6.18M
-15.2% YoY
|
| EBIT |
2.02M
est: -6.64M (+130.4%)
|
-2.29M
est: -8.55M (+73.3%)
|
-4.82M
est: -7.14M (+32.5%)
|
-10.13M
est: -8.22M (-23.2%)
|
-6.64M
-6.64M – -6.64M
+19.2% YoY
|
-8.55M
-8.55M – -8.55M
-28.7% YoY
|
-7.14M
-7.14M – -7.14M
+16.5% YoY
|
-8.22M
-8.22M – -8.22M
-15.2% YoY
|
| Net Income |
728.6K
|
-4.30M
est: 214.9K (-2,100.2%)
|
-9.45M
est: 1.00M (-1,042.5%)
|
-11.13M
|
—
— – —
|
214.9K
214.9K – 214.9K
|
1.00M
1.00M – 1.00M
+366.5% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
5.73M
est: 10.64M (-46.2%)
|
7.72M
est: 13.69M (-43.6%)
|
9.63M
est: 11.43M (-15.7%)
|
8.94M
est: 13.16M (-32.1%)
|
10.64M
10.64M – 10.64M
-19.2% YoY
|
13.69M
13.69M – 13.69M
+28.7% YoY
|
11.43M
11.43M – 11.43M
-16.5% YoY
|
13.16M
13.16M – 13.16M
+15.2% YoY
|
| EPS |
0.88
|
-4.30
est: 0.20 (-2,260.3%)
|
-8.40
est: 0.93 (-1,004.5%)
|
-10.30
|
—
— – —
|
0.20
0.20 – 0.20
|
0.93
0.93 – 0.93
+366.5% YoY
|
—
— – —
-100.0% YoY
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Mark William Waldron | Chief Executive Officer & Chairman | 280.0K | male |
| Joseph Lawrence Starr | Chief Operating Officer & Director | 209.5K | male |
| Michal J. Holub | Chief Financial Officer | 113.2K | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for VIBEF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
